Database / Pharmaceutical impurity
Pharmaceutical impurityPitavastatin Impurity 66
Pitavastatin Impurity 66 is listed in the pharmaceutical impurity collection under CAS 121659-86-7. Its represented structure has formula C20H16FNO2 and a calculated molecular weight of 321.35 g/mol.
2D chemical structure
Chemical identity
- Catalog name
- Pitavastatin Impurity 66
- Common name
- Pitavastatin Impurity 66
- Chemical name
- methyl 2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-carboxylate
- CAS
- 121659-86-7
- SMILES
- COC(=O)c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1
- InChI
- InChI=1S/C20H16FNO2/c1-24-20(23)18-17(12-8-10-14(21)11-9-12)15-4-2-3-5-16(15)22-19(18)13-6-7-13/h2-5,8-11,13H,6-7H2,1H3
- InChIKey
- RNXQZVFWKIPEOJ-UHFFFAOYSA-N
- Associated API
- Pitavastatin
Record ID: Af0c41fa2270a
Computed properties
C20H16FNO2 Molecular formula
321.351 g/molMolecular weight
321.1165 DaMonoisotopic exact mass
39.19 ŲTopological polar surface area
4.7049 Calculated LogP (Wildman–Crippen)
90.4515 cm³/molMolar refractivity (Wildman–Crippen)
3 countHydrogen-bond acceptors
0 countHydrogen-bond donors
Descriptors are calculated from the displayed SMILES. Calculated LogP is not a measured partition coefficient or a pH-specific LogD.
Molecular descriptor profile
Structural feature counts
Element composition
Radar scale: 0–100 percentile within 25,771 distinct represented structures in this release, using the midpoint rank for ties. Larger values indicate a higher descriptor rank, not greater safety or toxicity. Element counts include hydrogen and combine isotopes under each element.
Radar values and percentile reference
| Descriptor | Value | Percentile |
|---|---|---|
| Molecular weight | 321.351 | 50.52 |
| Calculated LogP (Wildman–Crippen) | 4.7049 | 86.99 |
| Topological polar surface area | 39.19 | 21.36 |
| Hydrogen-bond acceptors | 3 | 33.13 |
| Hydrogen-bond donors | 0 | 11.28 |
| Rotatable bonds (strict) | 3 | 37.08 |
Complete molecular descriptors
| Property | Calculated value | Unit / type |
|---|---|---|
| Molecular formula | C20H16FNO2 | dimensionless |
| Molecular weight | 321.351 | g/mol |
| Monoisotopic exact mass | 321.1165 | Da |
| Topological polar surface area | 39.19 | Ų |
| Calculated LogP (Wildman–Crippen) | 4.7049 | dimensionless |
| Molar refractivity (Wildman–Crippen) | 90.4515 | cm³/mol |
| Hydrogen-bond acceptors | 3 | count |
| Hydrogen-bond donors | 0 | count |
| Rotatable bonds (strict) | 3 | count |
| Heavy atoms | 24 | count |
| Heteroatoms | 4 | count |
| Rings | 4 | count |
| Aromatic rings | 3 | count |
| Aliphatic rings | 1 | count |
| Saturated rings | 1 | count |
| Aromatic heterocycles | 1 | count |
| Aliphatic heterocycles | 0 | count |
| Saturated heterocycles | 0 | count |
| Aromatic carbocycles | 2 | count |
| Aliphatic carbocycles | 1 | count |
| Fraction of sp³ carbon atoms | 0.2 | fraction |
| Formal charge | 0 | e |
| Disconnected components | 1 | count |
| Isotopically specified atoms | 0 | count |
| Potential atom stereocenters | 0 | count |
| Unspecified atom stereocenters | 0 | count |
| Spiro atoms | 0 | count |
| Bridgehead atoms | 0 | count |
| Labute approximate surface area | 138.6493 | Ų |
| Valence electrons | 120 | count |
| Radical electrons | 0 | count |
| Bertz complexity | 930.2718 | index |
| Balaban J | 2.1 | index |
Ring categories overlap and should not be summed. No toxicity result, PDE, HBEL or acceptable intake is inferred from these descriptors.
Toxicological services and resources for Pitavastatin Impurity 66
Qualification and safety assessment of Pitavastatin Impurity 66
Explore toxicological qualification of Pitavastatin Impurity 66 and ICH M7 mutagenic impurity assessment of Pitavastatin Impurity 66 for evaluation of this impurity in its pharmaceutical context.
Where data gaps need to be addressed, resources include read-across assessment for Pitavastatin Impurity 66 and acceptable intake and limit justification for Pitavastatin Impurity 66. The relevant approach depends on the available evidence, exposure and duration of use.
Related Altox services and technical resources
- ICH M7 Mutagenic Impurity Assessment
- Genotoxic Impurity Risk Assessment
- (Q)SAR Mutagenicity Assessment
- Mutagenic and Non-Mutagenic Impurity Assessment
- Toxicological Qualification of Impurities and Degradation Products
- Toxicological Read-Across Assessment
- Impurity Specification Setting and Limit Justification
- Acceptable Intake (AI) Assessment and Limit Derivation
Other catalogue designations with the same represented structure
These are separate catalogue entries; shared structure does not establish interchangeable pharmacopoeial designations.
Identity sources and calculation method
Identifiers originate from the source catalogues and available public identity records. InChI and InChIKey on this page are generated from the displayed SMILES. RDKit validation checks the molecular representation; it does not independently verify every catalogue assignment.
Discuss an assessment for Pitavastatin Impurity 66
Explore Altox services and software through the Altox Pharma-Hub.